Extended Inhalant Allergy Panel

The Extended Inhalant Allergy Panel is a laboratory blood test that measures specific immunoglobulin E, or specific IgE, against 90 inhalant allergen components. It is intended for a broader assessment of possible sensitization to airborne substances that may be encountered outdoors, indoors, at home, at work, or during particular seasons.

The test may be considered when symptoms include sneezing, a runny and blocked nose, itchy, red and watery eyes, coughing, wheezing and shortness of breath, or rash and itchy skin. The pattern is particularly relevant when symptoms repeatedly occur during a pollen season, after entering a dusty room, around animals, in damp environments, or after another recognizable exposure.

What the extended panel analyzes

The panel examines specific IgE responses to inhalant allergen extracts and molecular allergen components. Its confirmed scope includes 90 components associated with major groups of airborne allergens, including:

• grass pollen
• tree pollen
• weed pollen
• house dust mites
• molds and other microorganisms
• CCD markers used when assessing possible cross-reactivity

An allergen extract contains a mixture of proteins from one allergen source. Molecular component testing examines individual proteins within that source. Combining these approaches can provide more detail than testing only a limited number of whole allergen extracts.

This additional detail may help distinguish a likely primary sensitization from positive results caused by structurally similar proteins found in different pollens or other allergen sources. It may also help explain why several related allergens appear positive on the same report. Interpretation still depends on the person’s symptoms and exposure history.

How it differs from the basic inhalant panel

The basic inhalant allergy panel includes 45 allergenic components, while the extended panel includes 90. The extended option therefore covers a wider selection of allergen sources and molecular components and may be useful when symptoms involve several seasons or environments, when previous testing has not clearly identified the likely trigger, or when more detailed differentiation is needed.

A larger panel is not automatically the better choice for every person. Someone with a clear and limited exposure pattern may obtain enough information from a more focused test. Broader testing is generally more relevant when symptoms are persistent, involve multiple organ systems, occur after different exposures, or do not match earlier results.

Who may consider this test

The panel may be considered by adults or children with recurrent symptoms that are clinically compatible with an inhalant allergy. Examples include seasonal nasal and eye symptoms, year-round symptoms in bedrooms or other indoor spaces, respiratory symptoms around animals or dust, and skin symptoms that repeatedly appear with a suspected airborne exposure.

The test is not intended as indiscriminate screening in a person without symptoms or a meaningful exposure history. It also does not replace an examination when symptoms may have infectious, structural, irritant, dermatological, or non-allergic causes.

Key facts

• Test type: specific IgE blood test
• Confirmed scope: 90 inhalant allergen components
• Sample: one tube of venous blood
• Fasting: not required
• Regular therapy: interruption is not required under the confirmed preparation instructions
• Skin exposure: allergens are not applied to the skin during the test

How the testing process works

Step 1: Review the symptom and exposure pattern

Before testing, it is useful to record when symptoms began, whether they are seasonal or present throughout the year, and whether they worsen around pollen, dust, animals, damp rooms, mold, or occupational materials. This information helps determine whether an extended panel is appropriate and later supports interpretation of the report.

Step 2: Prepare for blood collection

Fasting is not required. The confirmed preparation instructions also state that regular therapy does not need to be interrupted for this blood test. Medication should not be changed independently, particularly when it is used to control asthma, breathing difficulties, or a previous severe allergic reaction.

Step 3: Blood sample collection

One tube of venous blood is collected. The collection itself usually takes only a few minutes. The sample is then analyzed for specific IgE directed against the included allergen extracts and molecular components.

Step 4: Laboratory analysis and report

The report identifies components for which specific IgE was detected and presents the measured response according to the testing method. The exact reporting time should be confirmed when the test is arranged because a test-specific turnaround time has not been publicly specified.

Step 5: Interpret the findings in clinical context

The results should be compared with the timing, type, and severity of symptoms and with realistic exposure to the identified allergen. Depending on the findings, further evaluation may include a clinical examination, respiratory assessment, skin evaluation, targeted testing, or discussion of exposure reduction and treatment options.

What a positive result means

A positive specific IgE result shows sensitization, meaning that the immune system has produced IgE antibodies that recognize the tested allergen component. Sensitization alone does not prove that exposure to that allergen causes clinically relevant symptoms.

For example, a pollen component may be positive even when the person does not experience symptoms during that pollen season. Conversely, the result becomes more clinically meaningful when the same exposure repeatedly precedes nasal, eye, breathing, or skin symptoms.

Some positive findings may reflect cross-reactivity. This occurs when IgE recognizes similar proteins in different allergen sources. CCD reactivity can also contribute to multiple positive laboratory results that may not correspond to separate clinically important allergies. Molecular components and CCD markers can support differentiation, but they do not replace clinical assessment.

Limitations of the panel

A negative result does not exclude every possible allergy because the panel assesses only the included components. It also does not exclude non-allergic rhinitis, irritation from smoke or chemicals, respiratory infection, structural nasal problems, asthma without demonstrable sensitization, or dermatological conditions unrelated to airborne allergens.

The panel does not by itself diagnose asthma, determine the severity of a future reaction, or establish that every positive allergen must be avoided. Broad avoidance measures based only on a laboratory report may be unnecessary and should not be introduced without relating the findings to actual symptoms and exposure.

Sudden or rapidly worsening breathing difficulty, swelling of the tongue or throat, faintness, or a widespread reaction requires urgent medical assessment rather than routine allergy testing.

What to send with an inquiry

When sending an inquiry through ZagrebMed, include a short description of the symptoms, their duration, seasonality, suspected triggers, relevant home or workplace exposures, current medication, and any previous allergy test results. Mention whether symptoms affect the nose, eyes, breathing, or skin and whether they occur together.

This information can help clarify whether the extended panel, the basic inhalant panel, a more targeted specific IgE test, or a clinical consultation is the more appropriate next step. You can send an inquiry to arrange testing and confirm the current reporting time.